Filing Flows › Immucell (ICCC) › Q2 2026
Immucell (ICCC) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
Immucell (ICCC) reported revenue of $7.2M for the second quarter 2026 (Q2 2026), +12% from a year earlier and -31% from the quarter before. Operating margin was 26.9%, net earnings $1.8M (25.5% of revenue).
Immucell, Q2 2026: revenue $7.2M (+12% year over year), operating margin 26.9%, net earnings $1.8M, operating cash flow $3.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.2M | -31% | +12% |
| Gross profit | $2.4M | -48% | -14% |
| Operating profit | $1.9M | -2% | +240% |
| Net earnings | $1.8M | -6% | +266% |
| Operating cash flow | $3.0M | -16% | +89% |
| Free cash flow | $2.3M | -33% | +58% |
What changed
Revenue was $7.2M in Q2 2026, up 12% year over year and down 31% from the previous quarter.
Gross margin was 33.9%, down 9.8 points from Q2 2025. Operating profit was $1.9M, a 26.9% margin (up 18.1 points year over year). Of the extra revenue versus Q2 2025, 184% reached operating profit, above the 9% margin then. Operating expenses fell 78% while revenue rose 12%. Net earnings were $1.8M, up 266% year over year. The effective tax rate was 2.4%.
Operating cash flow was $3.0M (up 89% year over year), 165% of net earnings. Non-cash charges added back $471K of depreciation and amortization and $240K of share-based compensation. Working capital and other items added $474K. Capital expenditures of $734K left free cash flow of $2.3M.
Questions
What was Immucell's revenue in the second quarter 2026?
Immucell (ICCC) reported revenue of $7.2M for the second quarter 2026 (Q2 2026), +12% from a year earlier and -31% from the quarter before.
Was Immucell profitable in the second quarter 2026?
Operating profit was $1.9M (26.9% of revenue) and net earnings $1.8M.
Source: Immucell 10-Q on SEC EDGAR.